Multimodal Imaging in Neurofibromatosis Type 1-associated Nerve Sheath Tumors

RoFo Fortschritte auf dem Gebiet der Rontgenstrahlen und der Bildgebenden Verfahren

Volumn 187, Issue 12, 2015, Pages 1084-1092

  Salamon, J ^a   Mautner, V F ^a   Adam, G ^a   Derlin, T ^b  

^a UNIVERSITY MEDICAL CENTER HAMBURG EPPENDORF   (Germany)

^b HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

MPNST; MRI; neurofibromatosis; NF1; PET

Indexed keywords

COMPUTER ASSISTED EMISSION TOMOGRAPHY; COMPUTER ASSISTED TOMOGRAPHY; CONTRAST ENHANCEMENT; DIAGNOSTIC IMAGING; DIFFERENTIAL DIAGNOSIS; DIFFUSION TENSOR IMAGING; DIFFUSION WEIGHTED IMAGING; HUMAN; MALIGNANT PERIPHERAL NERVE SHEATH TUMOR; MALIGNANT TRANSFORMATION; MULTIMODAL IMAGING; MULTIPARAMETRIC MAGNETIC RESONANCE IMAGING; NERVE SHEATH TUMOR; NEUROFIBROMATOSIS TYPE 1; PERIPHERAL NERVE TUMOR; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RADIATION EXPOSURE; REVIEW; TUMOR VOLUME; WHOLE BODY MRI; ADULT; CELL TRANSFORMATION; CHILD; CONSENSUS DEVELOPMENT; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; SENSITIVITY AND SPECIFICITY; SOFT TISSUE NEOPLASMS; WHOLE BODY IMAGING; YOUNG ADULT;

FLUORODEOXYGLUCOSE F 18;

ADULT; CELL TRANSFORMATION, NEOPLASTIC; CHILD; DIAGNOSIS, DIFFERENTIAL; FLUORODEOXYGLUCOSE F18; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIMODAL IMAGING; NERVE SHEATH NEOPLASMS; NEUROFIBROMATOSIS 1; PERIPHERAL NERVOUS SYSTEM NEOPLASMS; POSITRON-EMISSION TOMOGRAPHY; SENSITIVITY AND SPECIFICITY; SOFT TISSUE NEOPLASMS; TOMOGRAPHY, X-RAY COMPUTED; WHOLE BODY IMAGING; YOUNG ADULT;

EID: 84947491490     PISSN: 14389029     EISSN: 14389010     Source Type: Journal    
DOI: 10.1055/s-0035-1553505     Document Type: Review

References (50)

1. Lammert M., Friedman J. M., Kluwe L. et al. Prevalence of neurofibromatosis 1 in German children at elementary school enrollment. Arch Dermatol: 2005; 141 71 74
2. Huson S. M., Harper P. S., Compston D. A. Von Recklinghausen neurofibromatosis: a clinical and population study in south-east Wales. Brain: 1988; 111 1355 1381
3. Reynolds R. M., Browning G. G., Nawroz I. et al. Von Recklinghausen's neurofibromatosis: neurofibromatosis type 1. Lancet: 2003; 361 1552 1554
4. National Institutes of Health Consensus Development Conference Statement: neurofibromatosis. Bethesda, Md., USA, July 13-15, 1987. Neurofibromatosis: 1988; 1 172 178
5. Ferner R. E., Huson S. M., Thomas N. et al. Guidelines for the diagnosis and management of individuals with Neurofibromatosis 1 (NF1). J Med Genet: 2007; 44 81 88
6. Williams V. C., Lucas J., Babcock M. A. et al. Neurofibromatosis type 1 revisited. Pediatrics: 2009; 123 124 133
7. Hirbe A. C., Gutmann D. H. Neurofibromatosis type 1: a multidisciplinary approach to care. Lancet Neurol: 2014; 13 834 843
8. De Schepper S., Boucneau J., Vander Haeghen Y. et al. Café-au-lait spots in neurofibromatosis type 1 and in healthy control individuals: hyperpigmentation of a different kind? Arch Dermatol Res: 2006; 297 439 449
9. Duong T. A., Bastuji-Garin S., Valeyrie-Allanore L. et al. Evolving pattern with age of cutaneous signs in neurofibromatosis type 1: a cross-sectional study of 728 patients. Dermatology: 2011; 222 269 273
10. Boley S., Sloan J. L., Pemov A. et al. A quantitative assessment of the burden and distribution of Lisch nodules in adults with neurofibromatosis type 1. Invest Ophthalmol Vis Sci: 2009; 50 5035 5043
11. Jaremko J. L., MacMahon P. J., Torriani M. et al. Whole-body MRI in neurofibromatosis: incidental findings and prevalence of scoliosis. Skeletal Radiol: 2012; 41 917 923
12. Elefteriou F., Kolanczyk M., Schindeler A. et al. Skeletal abnormalities in neurofibromatosis type 1: approaches to therapeutic options. Am J Med Genet A: 2009; 149A 2327 2338
13. Friedman J. M., Arbiser J., Epstein J. A. et al. Cardiovascular disease in neurofibromatosis 1: report of the NF1 Cardiovascular Task Force. Genet Med: 2002; 4 105 111
14. Nguyen R., Mir T. S., Kluwe L. et al. Cardiac characterization of 16 patients with large NF1 gene deletions. Clin Genet: 2013; 84 344 349
15. Ferner R. E., Hughes R. A., Hall S. M. et al. Neurofibromatous neuropathy in neurofibromatosis 1 (NF1). J Med Genet: 2004; 41 837 841
16. Lehtonen A., Howie E., Trump D. et al. Behaviour in children with neurofibromatosis type 1: cognition, executive function, attention, emotion, and social competence. Dev Med Child Neurol: 2013; 55 111 125
17. Gutmann D. H., Parada L. F., Silva A. J. et al. Neurofibromatosis type 1: modeling CNS dysfunction. J Neurosci: 2012; 32 14087 14093
18. Ducatman B. S., Scheithauer B. W., Piepgras D. G. et al. Malignant peripheral nerve sheath tumors: a clinicopathologic study of 120 cases. Cancer: 1986; 57 2006 2021
19. Brems H., Beert E., de Ravel T. et al. Mechanisms in the pathogenesis of malignant tumours in neurofibromatosis type 1. Lancet Oncol: 2009; 10 508 515
20. Laycock-van Spyk S., Thomas N., Cooper D. N. et al. Neurofibromatosis type 1-associated tumours: their somatic mutational spectrum and pathogenesis. Hum Genomics: 2011; 5 623 690
21. Poyhonen M., Leisti E. L., Kytola S. et al. Hereditary spinal neurofibromatosis: a rare form of NF1? J Med Genet: 1997; 34 184 187
22. Korf B. R. Plexiform neurofibromas. Am J Med Genet: 1999; 89 31 37
23. Mautner V. F., Hartmann M., Kluwe L. et al. MRI growth patterns of plexiform neurofibromas in patients with neurofibromatosis type 1. Neuroradiology: 2006; 48 160 165
24. Ferner R. E., Gutmann D. H. International consensus statement on malignant peripheral nerve sheath tumors in neurofibromatosis. Cancer Res: 2002; 62 1573 1577
25. Evans D. G., Baser M. E., McGaughran J. et al. Malignant peripheral nerve sheath tumours in neurofibromatosis 1. J Med Genet: 2002; 39 311 314
26. Cai W., Kassarjian A., Bredella M. A. et al. Tumor burden in patients with neurofibromatosis types 1 and 2 and schwannomatosis: determination on whole-body MR images. Radiology: 2009; 250 665 673
27. Plotkin S. R., Bredella M. A., Cai W. et al. Quantitative assessment of whole-body tumor burden in adult patients with neurofibromatosis. PLoS One: 2012; 7 e35711
28. Kluwe L., Nguyen R., Vogt J. et al. Internal tumor burden in neurofibromatosis Type I patients with large NF1 deletions. Genes Chromosomes Cancer: 2012; 51 447 451
29. Tucker T., Friedman J. M., Friedrich R. E. et al. Longitudinal study of neurofibromatosis 1 associated plexiform neurofibromas. J Med Genet: 2009; 46 81 85
30. Nguyen R., Jett K., Harris G. J. et al. Benign whole body tumor volume is a risk factor for malignant peripheral nerve sheath tumors in neurofibromatosis type 1. J Neurooncol: 2014; 116 307 313
31. Matsumine A., Kusuzaki K., Nakamura T. et al. Differentiation between neurofibromas and malignant peripheral nerve sheath tumors in neurofibromatosis 1 evaluated by MRI. J Cancer Res Clin Oncol: 2009; 135 891 900
32. Wasa J., Nishida Y., Tsukushi S. et al. MRI features in the differentiation of malignant peripheral nerve sheath tumors and neurofibromas. Am J Roentgenol: 2010; 194 1568 1574
33. Derlin T., Tornquist K., Münster S. et al. Comparative effectiveness of 18F-FDG PET/CT versus whole-body MRI for detection of malignant peripheral nerve sheath tumors in neurofibromatosis type 1. Clin Nucl Med: 2013; 38 e19 e25
34. van Rijswijk C. S., Geirnaerdt M. J., Hogendoorn P. C. et al. Soft-tissue tumors: value of static and dynamic gadopentetate dimeglumine-enhanced MR imaging in prediction of malignancy. Radiology: 2004; 233 493 502
35. Demehri S., Belzberg A., Blakeley J. et al. Conventional and functional MR imaging of peripheral nerve sheath tumors: initial experience. AJNR Am J Neuroradiol: 2014; 35 1615 1620
36. Wilhelm T., Stieltjes B., Schlemmer H. P. Whole-Body-MR-Diffusion Weighted Imaging in Oncology. Fortschr Röntgenstr: 2013; 185 950 958
37. Chhabra A., Thakkar R. S., Andreisek G. et al. Anatomic MR imaging and functional diffusion tensor imaging of peripheral nerve tumors and tumorlike conditions. AJNR Am J Neuroradiol: 2013; 34 802 807
38. Warbey V. S., Ferner R. E., Dunn J. T. et al. [18F]FDG PET/CT in the diagnosis of malignant peripheral nerve sheath tumours in neurofibromatosis type-1. Eur J Nucl Med Mol Imaging: 2009; 36 751 757
39. 18F-FDG PET/CT for characterization of peripheral nerve sheath tumours in neurofibromatosis type 1. Eur J Nucl Med Mol Imaging 2013; 40: 685-692
40. Ferner R. E., Golding J. F., Smith M. et al. [18F]2-fluoro-2-deoxy-D-glucose positron emission tomography (FDG PET) as a diagnostic tool for neurofibromatosis 1 (NF1) associated malignant peripheral nerve sheath tumours (MPNSTs): a long-term clinical study. Ann Oncol: 2008; 19 390 394
41. Benz M. R., Czernin J., Dry S. M. et al. Quantitative F18-fluorodeoxyglucose positron emission tomography accurately characterizes peripheral nerve sheath tumors as malignant or benign. Cancer: 2010; 116 451 458
42. Moharir M., London K., Howman-Giles R. et al. Utility of positron emission tomography for tumour surveillance in children with neurofibromatosis type 1. Eur J Nucl Med Mol Imaging: 2010; 37 1309 1317
43. Brenner W., Friedrich R. E., Gawad K. A. et al. Prognostic relevance of FDG PET in patients with neurofibromatosis type-1 and malignant peripheral nerve sheath tumours. Eur J Nucl Med Mol Imaging: 2006; 33 428 432
44. Derlin T., Hagel C., Mautner V. F. Syndromic abdominal ganglioneuroma: a rare cause of false-positive findings in the F-18 FDG PET / CT in neurofibromatosis type 1. Fortschr Röntgenstr: 2014; 186 706 707
45. Salamon J., Veldhoen S., Apostolova I. et al. 18F-FDG PET/CT for detection of malignant peripheral nerve sheath tumours in neurofibromatosis type 1: tumour-to-liver ratio is superior to an SUVmax cut-off. Eur Radiol: 2014; 24 405 412
46. Combemale P., Valeyrie-Allanore L., Giammarile F. et al. Utility of 18F-FDG PET with a semi-quantitative index in the detection of sarcomatous transformation in patients with neurofibromatosis type 1. PLoS One: 2014; 9 e85954
47. Chirindel A., Chaudhry M., Blakeley J. et al. 18F-FDG PET/CT qualitative and quantitative evaluation in NF1 patients for Detection of Malignant Transformation - comparison of early to delayed imaging with and without liver activity normalization. J Nucl Med: 2015
48. Kumar A. J., Kuhajda F. P., Martinez C. R. et al. Computed tomography of extracranial nerve sheath tumors with pathological correlation. J Comput Assist Tomogr: 1983; 7 857 865
49. Cohen L. M., Schwartz A. M., Rockoff S. D. Benign schwannomas: pathologic basis for CT inhomogeneities. Am J Roentgenol: 1986; 147 141 143
50. Fortman B. J., Kuszyk B. S., Urban B. A. et al. Neurofibromatosis type 1: a diagnostic mimicker at CT. Radiographics: 2001; 21 601 612